Ocular Therapeutix reports Q3 2026 results, moves SOL-R endpoint to Week 40

Ocular Therapeutix reported its third quarter 2026 financial results and provided business updates. The company also updated the primary efficacy endpoint timing for its SOL-R trial to Week 40 to ensure trial integrity, with topline results now expected in the first quarter of 2028.

Detected & updated continuously · Source: Nebula